Objectives-To estimate the prevalence of solid renal tumors isoenhancing to kidneys in all vascular phases on contrast-enhanced sonography and to investigate whether they can be differentiated from pseudomasses.
W ith continuous improvement of ultrasound equipment, an increasing number of solid renal masses are detected incidentally in patients investigated for other purposes. In this context, the first clinically relevant differential diagnosis is between renal tumors and pseudomasses, such as hypertrophied columns of Bertin, fetal lobulations, and other anatomic variations that can simulate a focal renal mass on sonography. In most cases, the diagnosis of a pseudomass is reached with grayscale sonography and conventional Doppler modes. Unlike tumors, pseudomasses show the same cortical vasculature seen in the surrounding renal parenchyma. In particular, vessels branch from the interlobar up to the interlobular arteries and veins, and a medullary pyramid is often identified within them. 1 In rare instances, however, conventional Doppler modes do not allow differentiation between tumors and pseudomasses, and other imaging modalities are required.
Contrast-enhanced sonography is considered highly effective for differentiating between renal tumors and pseudomasses. Concordance approaching 100% with reference imaging modalities (contrast-enhanced computed tomography [CT] and magnetic resonance imaging [MRI] ) has been reported. 2 In fact, the use of contrast-enhanced sonography is recommended for this purpose by the current version of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) guidelines for the use of microbubble contrast agents in nonhepatic applications. 3 Differences in enhancement are the clues for differentiation. In most cases, enhancement of renal tumors differs from that of the surrounding renal cortex in at least 1 vascular phase, whereas pseudomasses are isoenhancing to kidneys in all phases.
2,4-6 Renal tumors, however, do not show a specific perfusion pattern. 7 Although no previous investigation reported on cases of renal tumors isoenhancing to the cortex in all vascular phases on contrast-enhanced sonography, such lesions can be rarely encountered in clinical practice. This issue raises concern about the ability of contrast-enhanced sonography to always differentiate true lesions from pseudomasses when specifically used for this purpose. The EFSUMB guidelines, in particular, acknowledge that the existence of renal tumors isoenhancing to the cortex in all vascular phases is a possible limitation for differentiation between renal tumors and anatomic variations. 3 The aim of our study was 2-fold: to estimate the frequency of tumors isoenhancing to the cortex on contrast-enhanced sonography and to identify features that allow their differentiation from pseudomasses.
Materials and Methods
This retrospective study was planned and conducted in accordance with the Declaration of Helsinki and good clinical practice rules and approved by the Ethics Committee of the corresponding author's institution. Data were processed without patient-identifying information. Hence, the requirement for informed consent was waived.
A computer search of the databases of 3 institutions was done for all contrast-enhanced sonographic investigations performed to evaluate the kidneys from 2002 to 2016. After removal of the personal identifiable information, the medical reports were read, and investigations performed to evaluate solid renal lesions or to differentiate a renal tumor from a pseudolesion were selected. Contrast-enhanced sonographic investigations performed for other purposes (ie, characterization of complex renal cysts, detection of ischemic areas, inflammatory changes, or follow-up of patients with tumor ablation) were excluded, as well as patients with no images and digital clips available for retrospective review. This study dealt with the appearance of renal tumors and pseudomasses on contrast-enhanced sonography, with the aim of estimating the frequency of tumors isoenhancing to the cortex and to identify features that allow their differentiation from pseudomasses. Therefore, retrieval of the clinical histories of all patients, demographics, and availability of other imaging studies performed either before or after contrast-enhanced sonography was not deemed necessary.
This process identified a total of 411 patients with pseudolesions (n 5 31) or solid renal tumors (n 5 380) investigated with contrast-enhanced sonography. If the report of the contrast-enhanced sonographic investigation described inhomogeneous enhancement of the tumor or enhancement different from the surrounding parenchyma in at least 1 vascular phase, the lesion was excluded, as well as tumors showing a pseudocapsule. They were not considered isoenhancing, as the presence of distinct rim enhancement around the lesion differentiated their vascularity from that of the surrounding parenchyma. 4, 8 If the report did not describe in detail the enhancement characteristics of the lesion, images and digital clips were reviewed. Eventually, 19 patients were found with tumors isoenhancing to the renal cortex in all vascular phases.
The contrast-enhanced sonographic studies were performed by abdominal radiologists who had at least 5 years of experience in imaging the kidneys with microbubble contrast agents. A variety of ultrasound equipment and contrast-specific, nondestructive modes were used (Table 1) . After a preliminary grayscale and color Doppler study, a bolus of sulfur hexafluoride filled microbubbles (SonoVue; Bracco SpA, Milan, Italy) was injected by using a 20-gauge cannula, followed by a 10-mL normal saline flush. According to the EFSUMB guidelines, 3 a different dose of the contrast agent was used for kidney imaging, ranging from 1.2 to 4.8 mL depending on the sensitivity of the equipment and on the type of transducer. The power of the ultrasonic beam was set to obtain minimum microbubble destruction. The transducer was moved during the contrast circulation to explore all lesion aspects, and real-time video clips were recorded for at least 3 minutes after microbubble injection and digitally stored.
Grayscale and color Doppler images and digital clips of the contrast-enhanced sonographic studies of the 19 patients with isoenhancing tumors and the 31 patients with pseudolesions were retrieved for retrospective review. In these cases, patients' sexes and ages at the time of the contrast-enhanced sonographic examinations, results of other imaging modalities, and histologic results of the imaged lesions, when present, were also retrieved from the archives.
Image Analysis
Sonograms and cine clips obtained during microbubble contrast agent administration were reviewed in random order by 2 independent radiologists with 20 and 10 years of experience in genitourinary imaging, respectively. The radiologists were blinded to whether the patient had a pseudomass or a renal tumor isoenhancing to the cortex in all phases, as well as to the findings of the reference procedures. Identifying information was masked.
The radiologists were asked to identify the target, to assess echogenicity compared to the kidney, and to determine whether it was intraparenchymal, was exophytic, or presented as focal thickening of the parenchyma. Then they were asked to assess whether it was possible to recognize within the target any segmental, interlobar, or arcuate arteries (within 2-3 seconds after microbubble arrival), followed by cortical enhancement and, eventually, by enhancement of the medulla. Medullary perfusion occurs later, with the outer medulla enhancing first, followed by gradual fill-in of the pyramids. 4, 9 In the kidney, 2 distinct vascular phases are recognized after microbubble injection: the cortical phase, in which enhancement of the cortical vessels is seen; followed by the parenchymal phase, in which both the cortex and medulla enhance. The elements taken into consideration during the retrospective review process are summarized in Table 2 .
After evaluating the grayscale appearances and enhancement characteristics of each examination, the readers were asked to indicate, independently, whether a tumor was present and to assign a confidence level in the diagnosis of a renal tumor according to a 7-degree scale. The criteria used are reported in Table 3 . For the purpose of our study, if no focal lesions or morphologic irregularities were found on contrast-enhanced sonography, the patient was considered not to have a tumor. No attempt was made to differentiate among different histologic type for the true renal masses.
Reference Procedures
The diagnosis of a renal tumor was confirmed with CT/ MRI in all cases, and the final histological diagnosis was obtained at surgery or biopsy in 12 of 19 patients. Of the remaining 7 lesions, 3 were angiomyolipomas with an obvious appearance on CT/MRI by the presence of macroscopic intralesional fat, and 4 were not operated or biopsied because of severe comorbidities (Table 4) . In these patients, diagnostic confirmation of tumor was based on disease progression on follow-up CT/MRI investigations. The diagnosis of a pseudomass was confirmed with CT/MRI in 11 of 31 cases. In the remaining patients, the renal appearance remained unchanged after a sonographic follow-up of at least 2 years.
Statistical Analysis
Evaluations were performed on a per-patient basis. If the patient had multiple masses/pseudomasses, only the largest was considered. A receiver operating characteristic (ROC) curve analysis was used to assess the overall confidence of diagnosis of a renal tumor. The 7-degree scale for confidence levels in the diagnosis of a renal tumor assigned by the 2 readers was used to perform the ROC curve analysis using dedicated software (JROCFIT; Johns Hopkins University, Baltimore, MD), and the areas under the ROC curve were compared by the method described by Hanley and McNeil. 10 Inter-reader agreement was assessed by using weighted j statistics calculated with commercially available software (MedCalc for Windows version 12.7.7.0; MedCalc Software, Mariakerke, Belgium). Agreement was graded as poor (j < 0.20), moderate (j > 0.20 and 0.40), fair (j > 0.40 and 0.60), good (j > 0.60 and 0.80), and very good (j 5 0.8-1.0). P < .05 was considered to indicate a statistically significant difference.
Results
The 19 patients in the study included 11 men and 8 women with an age range of 34 to 83 years (mean age 6 SD, 61 6 15 years; median age, 63 years). Nine of 19 (47%) tumors were on the left side. Lesions ranged in diameter from 0.8 to 3.4 cm (mean, 1.8 6 0.7 cm; median, 1.7 cm). Seven tumors were exophytic; 3 presented as focal thickening of the parenchyma; and 9 were intraparenchymal. None had vessels with normal architecture or had medullary pyramids identified in them at contrast-enhanced sonography. Three of 19 tumors were markedly hyperechoic to the kidney on grayscale sonography and proved to be angiomyolipomas at the reference procedures. Eleven of 19 were Markedly hypo/hyperechoic: clearly visible lesions presenting subjectively with considerable reduced/increased echogenicity compared to the surrounding renal parenchyma. Presence of the medulla within the target Contrast-enhanced sonography after cortex enhancement, progressing from the outer to inner medulla mildly hypoechoic or hyperechoic (Figure 1 ). Five of 19 were isoechoic on grayscale sonography (Table 5) . Most pseudomasses (25 of 31 [81%]) were on the left side. They were significantly larger than the tumors (range, 1.3-4.4 cm; mean, 2.7 6 0.8 cm; median, 2.3 cm; t test, P < .001). Twenty-three of 31 were isoechoic to kidneys on grayscale sonography; 8 were mildly hypoechoic or hyperechoic. Nine were exophytic; 13 presented as focal thickening of the parenchyma ( Figure 2) ; and 9 were intraparenchymal. On contrast-enhanced sonography, the more-experienced reader (20 years of experience in genitourinary imaging) recognized a medullary structure in 22 of 31 pseudomasses, whereas the less-experienced reader (10 years of experience) identified it in only 15 of them. Normal parenchymal vessel branching was seen on contrast-enhanced sonography in 14 and 13 pseudolesions by the readers, respectively. Results of the ROC curve analysis are summarized in Table 6 . Tumors were characterized effectively by both radiologists combining the grayscale appearance and enhancement characteristics (areas under the ROC curve, 0.997 and 0.969 for radiologists 1 and 2, respectively). The difference between the areas under the ROC curve between the radiologists was not statistically significant. The radiologists correctly characterized the target as a tumor in all but 1 patient, in whom the lesion was not sonographically visible. This patient had contrast-enhanced sonography for characterization of a complex cyst, and an additional lesion was identified in the same kidney on a contrast MRI study performed after contrast-enhanced sonography. Repeated contrastenhanced sonography under the guidance of the MRI findings failed to identify this lesion, which was also missed during the retrospective evaluation of images ( Figure 3 ). Pseudolesions were correctly identified by radiologist 1 in 30 of 31 patients and by radiologist 2 in 29 of 31 patients. Very good inter-radiologist agreement was found (weighted j 5 0.81). 
Discussion
In this article, a series of solid renal tumors isoenhancing to the renal cortex on contrast-enhanced sonography in all vascular phases is presented, and criteria are described to differentiate them from pseudomasses. Renal pseudomasses due to a hypertrophied column of Bertin, fetal lobulation, as well as dromedary or splenic humps are frequent anatomic variations that can simulate a true lesion on sonography. 11, 12 A fundamental sonographic criterion for the diagnosis of a pseudomass is echogenicity and an echo texture equal to those of the surrounding parenchyma, with the presence of medullary pyramids; however, this appearance is not always the case, since differences in echogenicity can be observed, and identification of pyramids can be difficult. 4, 13 In some cases, deformations of the renal boundaries, echogenicity differences produced by artifacts, and the impossibility of following the normal renal vessels on a color Doppler interrogation can make it impossible to differentiate pseudomasses from true focal lesions on conventional sonographic and Doppler modes. The mainstay of diagnosis and staging of renal tumors is contrast CT scanning. Magnetic resonance imaging is an alternative in select patients.
14 However, contrast-enhanced sonography can also have a role in the diagnosis of these lesions by increasing detection of the intrarenal vascularity. Kidneys enhance quickly and intensively after microbubble administration. Both the macrovasculature and the microvasculature can be investigated, the former within 1 to 3 seconds after microbubble arrival. Medullary perfusion follows cortical perfusion, with the outer medulla enhancing first, followed by gradual fill-in of the pyramids. 9 Then, according to the EFSUMB guidelines, 3 in our departments, contrast-enhanced sonography is increasingly used as an adjunct to CT/MRI in a variety of clinical situations related to the kidneys: among them, patients with suspected pseudotumors not solved with conventional Doppler modes, 15 cases with renal perfusion abnormalities, 16 complex cysts or renal masses with undetermined enhancement, 15, 17, 18 patients undergoing tumor ablation before treatment and during the follow-up, [19] [20] [21] and when a contrast study is needed in a patient with severe renal impairment. 22 Visualization of normal-appearing branching vessels from the hilum to the renal cortex is a very useful sign that no mass is present.
2 Furthermore, the enhancement pattern within an area of simple anatomic variation is synchronous with that of the other portions of the parenchyma, and both cortical and medullary vascularization can often be detected. In our study, this feature was highly specific, in keeping with previous investigations. 2, 15 In our study, abnormalities with a marked difference in echogenicity from the parenchyma on grayscale sonography were invariably true masses, and the role of contrast-enhanced sonography was limited. All pseudomasses were isoechoic to kidneys on grayscale sonography or, uncommonly, mildly hypoechoic or hyperechoic. Isoechoic tumors isoenhancing in all vascular phases could not be identified. This situation occurred in 1 patient in our study. In other situations, an evaluation of both B-mode and contrast-enhanced sonographic features was necessary to make a diagnosis. When the contrast-enhanced investigation was guided on a visible target, identified on grayscale sonography as a deformation of the renal profile or as an area of different echogenicity compared to the surrounding parenchyma, high sensitivity was reached in differentiating tumors from pseudomasses.
Although differences in vascularization remain highly suggestive of a tumor, isoenhancement to the renal cortex alone is not effective enough to exclude a focal renal mass. This situation occurs when the target shows the same enhancement pattern as the normal renal parenchyma, regarding not only the timing of enhancement but also the characteristics of its vascular architecture.
Also, according to our data, tumors isoenhancing in all phases are usually small, whereas pseudomasses are larger. This finding is not surprising, as larger renal tumors usually show inhomogeneous enhancement. 23 In our patients, tumors isoenhancing to kidneys in all phases on contrast-enhanced sonography were visible on contrast CT/MRI investigations. Therefore, they showed enhancement characteristics that were different from those of the surrounding parenchyma in at least 1 contrast phase. An explanation for this discrepancy is provided by the differences in contrast characteristics. 24 After intravenous administration of iodinated and gadolinium-based contrast agents for CT and MRI studies, respectively, 3 main different phases of renal enhancement are observed: namely, corticomedullary, nephrographic, and excretory. Renal mass detection is usually maximized in the nephrographic phase, which occurs during the passage of contrast material through the renal tubular system. [25] [26] [27] Microbubbles for contrast-enhanced sonography are true intravascular agents that do not undergo glomerular filtration and do not move into the interstitial spaces. Therefore, a contrast-enhanced sonographic study shows only passage of microbubbles through the renal vasculature. As the microbubble contrast concentration in the general circulation decreases, enhancement fades. There is no microbubble excretion into the urinary tract. On contrast-enhanced sonography, only 2 enhancement phases are recognized: a cortical phase, in which enhancement of the cortex is seen (15-30 second after contrast agent injection); and a parenchymal phase, in which enhancement of both the cortex and medulla is seen (25 seconds-4 minutes after contrast agent injection). Owing to different contrast kinetics and behavior, renal tumors may be less conspicuous on contrast-enhanced sonography compared to contrast-enhanced CT and MRI, especially when they are best identified with these techniques in the nephrographic phase. 4 Differences in signal acquisition may be another reason for the different visibility of solid renal lesions on contrast-enhanced sonography versus contrast CT/ MRI. It is well known that bubble behavior, including both scattering and attenuation, is nonlinear with respect to the ultrasonic pressure. Most importantly, data are log compressed before being processed into pixels of brightness for video presentation according to proprietary formulas. Then other algorithms are applied to provide "pleasing" images at visual perception, including the use of different postprocessing curves or color maps and signal filtering for edge enhancement. 28 These processes are necessary to obtain a scale of display brightness appropriate to human visual perception. With nondestructive contrast imaging, the order of magnitude of the signal from microbubbles is much lower than that of the signal from tissues on grayscale sonography. Therefore, clinical ultrasound scanners operate with a small dynamic range for better image presentation. Lowintensity signals are enhanced, whereas higher-intensity signals are compressed. 24 This factor may lead to signal saturation, making visual detection of subtle enhancement differences ineffective.
There were several limitations to our study, the most important being its retrospective design. This aspect might have introduced a case selection bias because some cases may have not been recorded for inclusion. Nonexophytic isoechoic tumors that were isovascular to the cortex might have been missed if other imaging modalities were not performed for other purposes or were not able to identify a distinct lesion. The incidence of tumors isoenhancing in all phases might, therefore, have been underestimated. Another limitation of our study was its relatively small size. Also, the reference standard had limitations. Not all patients underwent surgery, and we had no data to exclude or confirm the possibility of lesions with isoenhancing behavior on contrast-enhanced sonography that showed isoenhancement on contrast CT and MRI as well. Rare renal tumors identified on contrast-enhanced sonography and missed on contrast CT have, in fact, been described. 29 Another possible limitation may have arisen by the use of different ultrasound equipment, contrast-specific software, and doses of the microbubble contrast agent. As the kidney shows avid enhancement after microbubble injection, the use of small doses (1.2 mL) of the contrast agent is recommended. Some equipment, however, requires the use of higher doses. Small differences in enhancement might be overlooked because of signal saturation if an excessive dose of microbubbles is injected, thus overestimating the incidence of isoenhancing tumors in all phases.
In conclusion, in our study of solid renal masses investigated with contrast-enhanced sonography, the incidence of renal tumors that enhanced as much the surrounding renal parenchyma in all phases was not negligible, accounting for 5% of the lesions. Isoechoic tumors on conventional grayscale imaging can be missed if they are isoenhancing in all phases of contrastenhanced sonography. A variety of histotypes may have this contrast-enhanced sonographic appearance. Differential diagnosis with a pseudotumor is feasible, provided that the lesion is visible on grayscale sonography. Often the lesion is well delineated on grayscale sonography, with unequivocally different echogenicity from that of the adjacent parenchyma. As for renal pseudotumors, a normal perfusion pattern on contrast-enhanced sonography is the clue for the diagnosis, which means that the target shows exactly the same enhancement pattern as the normal renal parenchyma, regarding not only the timing of enhancement but also the characteristics of its vascular architecture. If these features are not shown, an isoenhancing tumor cannot be excluded on the basis of sonography, and further investigation with CT/MRI is recommended to confirm the diagnosis.
